Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective. Borse, R. H., Brown, C., Muszbek, N., Chaudhary, M. A., & Kachroo, S. Rheumatology and Therapy, 4(2):427–443, December, 2017. doi abstract bibtex INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime. The effectiveness outcome was quality-adjusted life-years (QALYs). Utilities were estimated by mapping Bath Ankylosing Spondylitis Functional Index scores, and the primary response measure was ≥50% improvement on the Bath Ankylosing Spondylitis Disease Activity Index at 12 weeks. Direct, medication, and AS management costs were included. Costs and outcomes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were comparable to each other and superior to conventional care. The incremental cost-effectiveness ratios (ICERs) for TNF-α inhibitors were £19,070-42,532 per QALY gained compared with conventional care. Analyses of the ICERs for each TNF-α inhibitor compared with conventional care demonstrated that golimumab was the most cost-effective treatment, and that adalimumab and etanercept were dominated by golimumab. Sensitivity analyses confirmed the robustness of these analyses. CONCLUSIONS: Golimumab may be considered a cost-effective treatment alternative for patients with active AS. With comparable costs and efficacy among TNF-α inhibitors, the choice of TNF-α inhibitor to treat AS is likely to be driven by patient and physician choice. FUNDING: Merck & Co., Inc.
@article{borse_cost-effectiveness_2017-1,
title = {Cost-{Effectiveness} of {Golimumab} in {Ankylosing} {Spondylitis} from the {UK} {Payer} {Perspective}},
volume = {4},
issn = {2198-6576},
doi = {10.1007/s40744-017-0083-1},
abstract = {INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime. The effectiveness outcome was quality-adjusted life-years (QALYs). Utilities were estimated by mapping Bath Ankylosing Spondylitis Functional Index scores, and the primary response measure was ≥50\% improvement on the Bath Ankylosing Spondylitis Disease Activity Index at 12 weeks. Direct, medication, and AS management costs were included. Costs and outcomes were discounted at 3.5\%. RESULTS: All TNF-α inhibitors were comparable to each other and superior to conventional care. The incremental cost-effectiveness ratios (ICERs) for TNF-α inhibitors were £19,070-42,532 per QALY gained compared with conventional care. Analyses of the ICERs for each TNF-α inhibitor compared with conventional care demonstrated that golimumab was the most cost-effective treatment, and that adalimumab and etanercept were dominated by golimumab. Sensitivity analyses confirmed the robustness of these analyses. CONCLUSIONS: Golimumab may be considered a cost-effective treatment alternative for patients with active AS. With comparable costs and efficacy among TNF-α inhibitors, the choice of TNF-α inhibitor to treat AS is likely to be driven by patient and physician choice. FUNDING: Merck \& Co., Inc.},
language = {eng},
number = {2},
journal = {Rheumatology and Therapy},
author = {Borse, R. H. and Brown, C. and Muszbek, N. and Chaudhary, M. A. and Kachroo, S.},
month = dec,
year = {2017},
pmid = {28956301},
pmcid = {PMC5696295},
keywords = {Ankylosing spondylitis, Cost-effectiveness, Golimumab, TNF-α inhibitor, UK},
pages = {427--443},
}
Downloads: 0
{"_id":"gS7gdfYMSb95bGBeQ","bibbaseid":"borse-brown-muszbek-chaudhary-kachroo-costeffectivenessofgolimumabinankylosingspondylitisfromtheukpayerperspective-2017","authorIDs":[],"author_short":["Borse, R. H.","Brown, C.","Muszbek, N.","Chaudhary, M. A.","Kachroo, S."],"bibdata":{"bibtype":"article","type":"article","title":"Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective","volume":"4","issn":"2198-6576","doi":"10.1007/s40744-017-0083-1","abstract":"INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime. The effectiveness outcome was quality-adjusted life-years (QALYs). Utilities were estimated by mapping Bath Ankylosing Spondylitis Functional Index scores, and the primary response measure was ≥50% improvement on the Bath Ankylosing Spondylitis Disease Activity Index at 12 weeks. Direct, medication, and AS management costs were included. Costs and outcomes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were comparable to each other and superior to conventional care. The incremental cost-effectiveness ratios (ICERs) for TNF-α inhibitors were £19,070-42,532 per QALY gained compared with conventional care. Analyses of the ICERs for each TNF-α inhibitor compared with conventional care demonstrated that golimumab was the most cost-effective treatment, and that adalimumab and etanercept were dominated by golimumab. Sensitivity analyses confirmed the robustness of these analyses. CONCLUSIONS: Golimumab may be considered a cost-effective treatment alternative for patients with active AS. With comparable costs and efficacy among TNF-α inhibitors, the choice of TNF-α inhibitor to treat AS is likely to be driven by patient and physician choice. FUNDING: Merck & Co., Inc.","language":"eng","number":"2","journal":"Rheumatology and Therapy","author":[{"propositions":[],"lastnames":["Borse"],"firstnames":["R.","H."],"suffixes":[]},{"propositions":[],"lastnames":["Brown"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Muszbek"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Chaudhary"],"firstnames":["M.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Kachroo"],"firstnames":["S."],"suffixes":[]}],"month":"December","year":"2017","pmid":"28956301","pmcid":"PMC5696295","keywords":"Ankylosing spondylitis, Cost-effectiveness, Golimumab, TNF-α inhibitor, UK","pages":"427–443","bibtex":"@article{borse_cost-effectiveness_2017-1,\n\ttitle = {Cost-{Effectiveness} of {Golimumab} in {Ankylosing} {Spondylitis} from the {UK} {Payer} {Perspective}},\n\tvolume = {4},\n\tissn = {2198-6576},\n\tdoi = {10.1007/s40744-017-0083-1},\n\tabstract = {INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime. The effectiveness outcome was quality-adjusted life-years (QALYs). Utilities were estimated by mapping Bath Ankylosing Spondylitis Functional Index scores, and the primary response measure was ≥50\\% improvement on the Bath Ankylosing Spondylitis Disease Activity Index at 12 weeks. Direct, medication, and AS management costs were included. Costs and outcomes were discounted at 3.5\\%. RESULTS: All TNF-α inhibitors were comparable to each other and superior to conventional care. The incremental cost-effectiveness ratios (ICERs) for TNF-α inhibitors were £19,070-42,532 per QALY gained compared with conventional care. Analyses of the ICERs for each TNF-α inhibitor compared with conventional care demonstrated that golimumab was the most cost-effective treatment, and that adalimumab and etanercept were dominated by golimumab. Sensitivity analyses confirmed the robustness of these analyses. CONCLUSIONS: Golimumab may be considered a cost-effective treatment alternative for patients with active AS. With comparable costs and efficacy among TNF-α inhibitors, the choice of TNF-α inhibitor to treat AS is likely to be driven by patient and physician choice. FUNDING: Merck \\& Co., Inc.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Rheumatology and Therapy},\n\tauthor = {Borse, R. H. and Brown, C. and Muszbek, N. and Chaudhary, M. A. and Kachroo, S.},\n\tmonth = dec,\n\tyear = {2017},\n\tpmid = {28956301},\n\tpmcid = {PMC5696295},\n\tkeywords = {Ankylosing spondylitis, Cost-effectiveness, Golimumab, TNF-α inhibitor, UK},\n\tpages = {427--443},\n}\n\n","author_short":["Borse, R. H.","Brown, C.","Muszbek, N.","Chaudhary, M. A.","Kachroo, S."],"bibbaseid":"borse-brown-muszbek-chaudhary-kachroo-costeffectivenessofgolimumabinankylosingspondylitisfromtheukpayerperspective-2017","role":"author","urls":{},"keyword":["Ankylosing spondylitis","Cost-effectiveness","Golimumab","TNF-α inhibitor","UK"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","creationDate":"2019-10-29T15:53:48.279Z","downloads":0,"keywords":["ankylosing spondylitis","cost-effectiveness","golimumab","tnf-α inhibitor","uk"],"search_terms":["cost","effectiveness","golimumab","ankylosing","spondylitis","payer","perspective","borse","brown","muszbek","chaudhary","kachroo"],"title":"Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective","year":2017,"dataSources":["sMi9tjFo5gDXmBZje","ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","zeMwFvgpdRkYAkfoD","v8uQmZsBpiqycmskv"]}